

**AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs**

**Decision Making Support Tool**

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0047	
Drug name and formulations:	Sodium chloride 7% solution for inhalation (Resp-Ease® 7%)	
<b>Criteria</b>	<b>Example</b>	<b>Committee Consensus</b>
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Same as current formulary option
Clinical effectiveness	<i>Established licensed product</i>	Same as current formulary option
Strength of evidence		Same as current formulary option
Cost effectiveness or resource impact	<i>£</i>	Lower acquisition cost than current formulary option.
Place of therapy relative to available treatments	<i>1/2<sup>nd</sup> tier</i>	First line- replaces current formulary option
National guidance and priorities	<i>NICE, MTRAC</i>	N/A
Local health priorities	<i>CCG views</i>	CCGs support
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	None

**Decision Summary**

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	GREEN- Cost-effective replacement of current formulary option. Remove Nebusal® from formulary.
Implementation requirements:	
Implementation monitoring:	